Karen Herman, MD
Family Medicine · El Paso, TXNPI 1386645752
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,102 of the $33,242 with a category attached, or 63.5%. Lumenis BE Inc accounts for 87.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $21,378 and has fallen 94.1% since, to $1,255 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $268.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$29K
- AbbVie$1K
- Merz North America, Inc.$557
- Galderma Laboratories, L.p.$461
- Incyte Corporation$287
- Pfizer$281
- plus $1K from 21 others
Across 13 payments — averaging $12,431 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Taro Pharmaceuticals USA, Inc.$162K
What the payments were for
- Speaking & faculty fees$21,10263%
- Food & beverage$12,02736%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 2 | $29,092 |
| AbbVie(2 entities) | 25 | $1,147 |
| Merz North America, Inc. | 8 | $557 |
| Galderma Laboratories, L.p. | 10 | $461 |
| Incyte Corporation | 9 | $287 |
| Pfizer | 33 | $281 |
| Johnson & Johnson | 5 | $202 |
| Lumenis, Inc | 1 | $168 |
| Impulse Dynamics (USA) Inc. | 1 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $114 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $106 |
| Sun Pharmaceutical Industries Inc. | 1 | $97 |
| AstraZeneca | 1 | $94 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| Boston Scientific | 1 | $59 |
| Dermira, Inc. | 2 | $44 |
| Tactile Systems Technology Inc | 3 | $42 |
| Organon | 2 | $39 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
| Almirall LLC | 1 | $20 |
| VYNE Pharmaceuticals Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Aclaris Therapeutics, Inc. | 1 | $12 |
| Prugen, Inc. Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,242 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 11 | $51,155 |
| Imiquimod | 16 | $517 |
Paid to pharmacies, not to this prescriber.
Other family medicine in El Paso
- Edward LeyvaEl Paso$91K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.